Drug intelligence / Profile preview

BW-201

Development stage: Unknown
Lead developer: Beijing Baiyi Wuyou Technology Development
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BW-201 is an investigational respiratory syncytial virus (RSV) vaccine candidate developed by Beijing Baiyi Wuyou Technology Development Co., Ltd. It is formulated with an adjuvant system designated as Adj 2 to enhance the immune response. The vaccine is intended for the prevention of RSV infection and associated lower respiratory tract disease (LRTD). As of early 2025, BW-201 is in Phase 1 clinical development in China, where it is being evaluated for safety, tolerability, and immunogenicity in healthy adults following a single dose.

Beyond the preview

Go deeper on BW-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW-201.

Explore the full profile